Enter NYXI with its updated Hyperion 2 Joy-Con pads, pitched as "the ultimate replacement" for the real Mc-Con. They don't ...

Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR™ (sotatercept-csrk) Early and Move to Final ...

In a report released on January 30, Daina Graybosch from Leerink Partners maintained a Buy rating on Merck & Company (MRK – Research ...

Brooks Running often refreshes its markdown page but in a rare deal, the Hyperion is seeing a markdown as low as $84.

MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...

Merck (MRK) announced the Phase 3 HYPERION study evaluating WINREVAIR versus placebo in recently diagnosed adults with pulmonary arterial ...

A phase 3 trial evaluating sotatercept-csrk (Winrevair™) in adults with pulmonary arterial hypertension (PAH; World Health Organization Group 1) ...

In close partnership with ALLIED Feather + Down (AF+D) and premium performance wear manufacturer Active Apparel Group, Templa ...

All patients in the trial will have the opportunity to resume or begin treatment with Winrevair, the company said.

US pharma giant Merck & Co today revealed an early stop to the Phase III HYPERION study evaluating Winrevair (sotatercept-csrk) versus placebo (both in combination with background therapy) in recently ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...